-
Je něco špatně v tomto záznamu ?
NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma
Z. Strizova, P. Taborska, D. Stakheev, S. Partlová, K. Havlova, S. Vesely, J. Bartunkova, D. Smrz,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem
Grantová podpora
NV16-28135A
MZ0
CEP - Centrální evidence projektů
- MeSH
- antigeny CD31 metabolismus MeSH
- buňky NK imunologie metabolismus MeSH
- cytotoxicita imunologická MeSH
- karcinom z renálních buněk imunologie patologie chirurgie MeSH
- ledviny cytologie imunologie patologie chirurgie MeSH
- lidé středního věku MeSH
- lidé MeSH
- ligand Fas metabolismus MeSH
- nádory ledvin imunologie patologie chirurgie MeSH
- nefrektomie MeSH
- protein TRAIL metabolismus MeSH
- průtoková cytometrie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- separace buněk MeSH
- T-lymfocyty imunologie metabolismus MeSH
- tumor infiltrující lymfocyty imunologie metabolismus MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
OBJECTIVES: Renal cell carcinoma (RCC) is the most lethal urologic malignancy with increasing incidence worldwide. The conventional treatment strategies for advanced or recurrent RCC are not efficient and show considerable toxicities. Adoptive cell transfer (ACT) has become a promising treatment option for multiple cancers, particularly in combination with other therapeutic approaches. ACT often utilizes extensively in vitro expanded tumor-infiltrating lymphocytes (TILs). However, TILs are a very heterogeneous mix of cell populations and only those populations that have a cytotoxic and migratory potential are thought to deliver a therapeutic impact in ACT. The identification and localization of these therapeutically potent populations are therefore needed. METHODS AND MATERIALS: A total number of 57 tissue samples from 19 RCC patients who underwent radical nephrectomy was analyzed. The tissue samples were obtained from the tumor, peritumoral tissue, and the adjacent healthy renal tissue. The tissues were sliced, enzymatically dissociated into single cell suspensions and the obtained cells further analyzed by flow cytometry for the expression of markers of lymphocyte cytotoxicity - TRAIL and FasL, and a surrogate marker of lymphocyte migratory activity - PECAM-1. The analyzed data were next correlated with the clinical and histopathological data. RESULTS: Non-clear cell RCC (non-ccRCC) tumors showed a significantly decreased tumor infiltration with TRAIL+FasL+ NK cells but elevated infiltration with FasL+PECAM-1+ T cells as compared with clear cell RCC (ccRCC) tumors. Further analyses revealed that the peritumoral tissue of ccRCC patients is a reservoir of TRAIL+FasL+, TRAIL+PECAM-1+, or FasL+PECAM-1+ NK and T cells. CONCLUSIONS: The cytotoxic/migratory lymphocytes were identified in tumors of ccRCC patients. These lymphocytes became excluded from the tumor and accumulated in the patient's peritumoral tissue.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025815
- 003
- CZ-PrNML
- 005
- 20201222155446.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.urolonc.2019.03.014 $2 doi
- 035 __
- $a (PubMed)31030972
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Strizova, Zuzana $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
- 245 10
- $a NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma / $c Z. Strizova, P. Taborska, D. Stakheev, S. Partlová, K. Havlova, S. Vesely, J. Bartunkova, D. Smrz,
- 520 9_
- $a OBJECTIVES: Renal cell carcinoma (RCC) is the most lethal urologic malignancy with increasing incidence worldwide. The conventional treatment strategies for advanced or recurrent RCC are not efficient and show considerable toxicities. Adoptive cell transfer (ACT) has become a promising treatment option for multiple cancers, particularly in combination with other therapeutic approaches. ACT often utilizes extensively in vitro expanded tumor-infiltrating lymphocytes (TILs). However, TILs are a very heterogeneous mix of cell populations and only those populations that have a cytotoxic and migratory potential are thought to deliver a therapeutic impact in ACT. The identification and localization of these therapeutically potent populations are therefore needed. METHODS AND MATERIALS: A total number of 57 tissue samples from 19 RCC patients who underwent radical nephrectomy was analyzed. The tissue samples were obtained from the tumor, peritumoral tissue, and the adjacent healthy renal tissue. The tissues were sliced, enzymatically dissociated into single cell suspensions and the obtained cells further analyzed by flow cytometry for the expression of markers of lymphocyte cytotoxicity - TRAIL and FasL, and a surrogate marker of lymphocyte migratory activity - PECAM-1. The analyzed data were next correlated with the clinical and histopathological data. RESULTS: Non-clear cell RCC (non-ccRCC) tumors showed a significantly decreased tumor infiltration with TRAIL+FasL+ NK cells but elevated infiltration with FasL+PECAM-1+ T cells as compared with clear cell RCC (ccRCC) tumors. Further analyses revealed that the peritumoral tissue of ccRCC patients is a reservoir of TRAIL+FasL+, TRAIL+PECAM-1+, or FasL+PECAM-1+ NK and T cells. CONCLUSIONS: The cytotoxic/migratory lymphocytes were identified in tumors of ccRCC patients. These lymphocytes became excluded from the tumor and accumulated in the patient's peritumoral tissue.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a karcinom z renálních buněk $x imunologie $x patologie $x chirurgie $7 D002292
- 650 _2
- $a separace buněk $7 D002469
- 650 _2
- $a cytotoxicita imunologická $7 D003602
- 650 _2
- $a ligand Fas $x metabolismus $7 D053222
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ledviny $x cytologie $x imunologie $x patologie $x chirurgie $7 D007668
- 650 _2
- $a nádory ledvin $x imunologie $x patologie $x chirurgie $7 D007680
- 650 _2
- $a buňky NK $x imunologie $x metabolismus $7 D007694
- 650 _2
- $a tumor infiltrující lymfocyty $x imunologie $x metabolismus $7 D016246
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nefrektomie $7 D009392
- 650 _2
- $a antigeny CD31 $x metabolismus $7 D019408
- 650 _2
- $a T-lymfocyty $x imunologie $x metabolismus $7 D013601
- 650 _2
- $a protein TRAIL $x metabolismus $7 D053221
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Taborska, Pavla $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
- 700 1_
- $a Stakheev, Dmitry $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
- 700 1_
- $a Partlová, Simona $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
- 700 1_
- $a Havlova, Klara $u Department of Urology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
- 700 1_
- $a Vesely, Stepan $u Department of Urology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
- 700 1_
- $a Bartunkova, Jirina $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
- 700 1_
- $a Smrz, Daniel $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic. Electronic address: daniel.smrz@lfmotol.cuni.cz.
- 773 0_
- $w MED00008671 $t Urologic oncology $x 1873-2496 $g Roč. 37, č. 7 (2019), s. 503-509
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31030972 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222155442 $b ABA008
- 999 __
- $a ok $b bmc $g 1599960 $s 1116501
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 37 $c 7 $d 503-509 $e 20190426 $i 1873-2496 $m Urologic oncology $n Urol Oncol $x MED00008671
- GRA __
- $a NV16-28135A $p MZ0
- LZP __
- $a Pubmed-20201125